1 Stock Up by 63% This Year That Could Double, According to Wall Street

Intellia is collaborating with Regeneron Pharmaceuticals , a leading biotech company, to develop nex-z. This therapy targets transthyretin (ATTR) amyloidosis, a disease caused by the buildup of abnormal transthyretin proteins in the heart, which can lead to heart problems or other issues. ATTR amyloidosis can either be hereditary or acquired with age. Intellia is conducting a phase 3 study for nex-z in ATTR amyloidosis with cardiomyopathy (a condition in which the heart has difficulty pumping blood), as wel ...